Your new experience awaits. Try the new design now and help us make it even better

METHODS article

Front. Genet.

Sec. Cancer Genetics and Oncogenomics

Volume 16 - 2025 | doi: 10.3389/fgene.2025.1541401

This article is part of the Research TopicCancer Cell Metabolism and Tumor Microenvironment RemodelView all 7 articles

Construction of a Novel Prognostic Model for Gastric Cancer Based on Pharmacokinetics-Related Genes and Comprehensive Prognostic Analysis

Provisionally accepted
  • First Hospital of Shanxi Medical University, Taiyuan, China

The final, formatted version of the article will be published soon.

Background: Absorption, distribution, metabolism, and excretion of drugs-related genes (ADMERGs), pivotal in cancer occurrence, development, and chemotherapy resistance, lack investigation in gastric cancer (GC). Thus, this study aims to build a prognostic model for gastric cancer utilizing ADMERGs.The GC-related datasets, including TCGA-GC, GSE62254, GSE163558 and GSE13911, as well as 298 ADMERGs, were retrieved in this study. Prognostic risk models associated with ADME were developed utilizing univariate Cox analysis, followed by additional refinement using the least absolute shrinkage and selection operator (LASSO). The entire pool of gastric cancer (GC) patient samples was partitioned into high and low-risk categories, delineated by the median value of their respective risk scores. Within these two distinct groups, we conducted enrichment analysis, immune infiltration, and prognostic evaluation of ADME-related prognostic genes to uncover their molecular mechanisms in GC. The construction of ceRNA regulatory networks was undertaken to analyse the prognostic gene regulatory mechanisms. We analyzed single-cell data in GC to investigate the mechanisms driving its onset and progression at the cellular level. Additionally, we validated the expression trends of prognostic genes in clinical samples using RT-qPCR.Results: A prognostic model for GC was established and validated, comprising five genes (UGT1A1, ADH4, ADH1B, CYP19A1, and GPX3). The levels of infiltration of 21 immune cells exhibited significant disparities between the two risk groups, such as central memory CD4 T cells, activated B cells, and mast cells. There was a notable positive correlation between the risk scores and mast cells and plasmacytoid dendritic cells. In the high-risk group, the TIDE scores were heightened. The single-cell dataset showed significant under-expression of ADH1B, ADH4, CYP19A1, and GPX3 in tumor samples. Finally, RT-qPCR showed that all the prognostic genes except for ADH4 were under-expressed in tumor tissues.We have developed and validated an innovative prognostic risk model for GC, revealing that elevated ADMERGs risk scores are indicative of unfavorable prognosis and diminished immunotherapy response. These findings furnish molecular evidence regarding the participation of ADMERGs in modulating the immune microenvironment and therapeutic responsiveness in GC.

Keywords: gastric cancer, ADME, Prognosis genes, immune environment, Prognostic model

Received: 13 Dec 2024; Accepted: 11 Aug 2025.

Copyright: © 2025 Zhang, Jia, Guo, Xiaole, Yao, Wu and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Yu Zhang, First Hospital of Shanxi Medical University, Taiyuan, China
Feng Wu, First Hospital of Shanxi Medical University, Taiyuan, China
He Huang, First Hospital of Shanxi Medical University, Taiyuan, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.